Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Consultation

NICE recommends ustekinumab for psoriatic arthritis

The National Institute for Health and Care Excellence (NICE) has issued draft guidance for consultation recommending that use of ustekinumab (Stelara; Janseen-Cilag) on the NHS for the treatment of psoriatic arthritis in specific circumstances. NICE rejected the drug in May 2014 but, following the introduction of a patient access scheme, has proposed a reversal of this decision. Further information can be found on the NICE website under technology appraisal number 313. Comments must be submitted by 7 January 2015. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067422

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.